Mediolanum International Funds Ltd Has $9.32 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Mediolanum International Funds Ltd increased its stake in Alnylam Pharmaceuticals by 283.2%, acquiring an additional 25,666 shares, bringing its total holdings to 34,729 shares worth approximately $9.32 million.
• Analysts have updated their price targets for Alnylam Pharmaceuticals, with estimates ranging from $320.00 to $404.00, reflecting a generally positive outlook with a consensus rating of "Moderate Buy".
• In related news, CEO Yvonne Greenstreet sold 31,640 shares valued at over $9.63 million, reducing her position by 39.26%, while maintaining 48,948 shares in the company.

Mediolanum International Funds Ltd grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 283.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 34,729 shares of the biopharmaceutical company's stock after purchasing an additional 25,666 shares during the quarter. Mediolanum International Funds Ltd's holdings in Alnylam Pharmaceuticals were worth $9,323,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of ALNY. Whipplewood Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Park Square Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Finally, Washington Trust Advisors Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 53.5% during the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 61 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several research reports. Jefferies Financial Group raised their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. BMO Capital Markets lifted their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research report on Tuesday, June 24th. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. Finally, HC Wainwright reissued a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $350.75.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $13.15 on Wednesday, hitting $343.70. 803,383 shares of the stock traded hands, compared to its average volume of 894,576. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $345.98. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The firm has a market capitalization of $44.81 billion, a PE ratio of -164.45 and a beta of 0.23. The business has a fifty day moving average price of $312.22 and a two-hundred day moving average price of $275.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company's revenue was up 20.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.